Skip to content

Daratumumab

Daratumumab is a monoclonal antibody targeting CD38, a protein highly expressed on the surface of multiple myeloma cells. It works by inducing cell death through immune-mediated mechanisms and direct apoptosis, making it a valuable treatment in oncology. Its relevance to longevity and health optimization lies in its potential to modulate the immune system and target cancerous cells, although its primary use is currently in cancer therapy.

Intelligence Profile

Research Papers

Research on daratumumab focuses on its application in various conditions, primarily multiple myeloma and certain transplant rejections.

  1. Kidney Allograft Rejection: A study in the Clinical Kidney Journal examined daratumumab's effects in antibody-mediated kidney allograft rejection. Using serial protocol biopsies, the study highlighted its potential therapeutic role, although detailed methodology such as sample size was not specified.

  2. Multiple Myeloma: Several studies focus on daratumumab for newly diagnosed and relapsed multiple myeloma. A paper from the Zhongguo Shi Yan Xue Ye Xue Za Zhi applied a multi-model study and clinical decision analysis to assess early death risk in newly diagnosed patients treated with daratumumab. Additionally, a retrospective analysis in the Asia-Pacific Journal of Clinical Oncology reviewed its use in relapsed or refractory cases in Australia, indicating effectiveness but lacking detailed quantitative data.

  3. Iron Deficiency and Treatment Complications: The British Journal of Haematology noted a high prevalence of iron deficiency among newly diagnosed multiple myeloma patients treated with daratumumab, suggesting the need for monitoring and management strategies.

  4. Treatment-Related Reactions: A prospective observational study in the Biological & Pharmaceutical Bulletin compared non-sedating and sedating antihistamines as premedications to prevent infusion-related reactions, highlighting options to minimize adverse effects during subcutaneous administration.

  5. Smoldering Multiple Myeloma: A phase II trial (NCT03236428) is currently not recruiting but is investigating daratumumab in high-risk MGUS and low-risk smoldering multiple myeloma, reflecting ongoing interest in its early-intervention potential.

Overall, clinical trials and papers show that daratumumab is extensively studied in multiple myeloma, with additional explorations in rejection management and safety improvements.

Disclaimer: This summary is for informational purposes only and not a substitute for professional medical advice.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.